Viking Therapeutics (VKTX) Stake Boosted by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its holdings in Viking Therapeutics (NASDAQ:VKTX) by 124.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 903,300 shares of the biotechnology company’s stock after purchasing an additional 500,700 shares during the period. Renaissance Technologies LLC owned 1.92% of Viking Therapeutics worth $3,667,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of VKTX. Creative Planning increased its stake in shares of Viking Therapeutics by 600.0% in the fourth quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 60,000 shares during the period. Victory Capital Management Inc. bought a new position in shares of Viking Therapeutics in the fourth quarter worth about $791,000. Opaleye Management Inc. bought a new position in shares of Viking Therapeutics in the fourth quarter worth about $1,951,000. Sphera Funds Management LTD. increased its stake in shares of Viking Therapeutics by 639.8% in the fourth quarter. Sphera Funds Management LTD. now owns 2,145,300 shares of the biotechnology company’s stock worth $8,710,000 after purchasing an additional 1,855,300 shares during the period. Finally, Cornerstone Capital Inc. bought a new position in shares of Viking Therapeutics in the fourth quarter worth about $352,000. Institutional investors and hedge funds own 18.34% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently weighed in on VKTX shares. Maxim Group reissued a “buy” rating and set a $8.00 target price on shares of Viking Therapeutics in a research report on Friday, February 2nd. BidaskClub downgraded Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 15th. Roth Capital set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 8th. ValuEngine raised Viking Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 12th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Viking Therapeutics in a research report on Monday, March 26th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $9.00.

VKTX stock opened at $4.71 on Friday. Viking Therapeutics has a twelve month low of $0.88 and a twelve month high of $7.36. The stock has a market cap of $242.44, a P/E ratio of -5.96 and a beta of 2.09.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. analysts anticipate that Viking Therapeutics will post -0.44 EPS for the current year.

WARNING: This news story was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://weekherald.com/2018/04/21/viking-therapeutics-vktx-stake-boosted-by-renaissance-technologies-llc.html.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics (NASDAQ:VKTX).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply